Stockscreener 앱 받기
2.97
22.22%
0.54
시간 외 거래:
3.13
0.16
+5.39%
전일 마감가:
$2.43
열려 있는:
$2.42
하루 거래량:
6.98M
Relative Volume:
1.12
시가총액:
$13.36M
수익:
$6.78M
순이익/손실:
$-14.74M
주가수익비율:
-0.1842
EPS:
-16.1258
순현금흐름:
$-8.51M
1주 성능:
+177.57%
1개월 성능:
+151.69%
6개월 성능:
-40.36%
1년 성능:
-65.45%
1일 변동 폭
$2.30
$3.00
1주일 범위
$1.58
$3.09
52주 변동 폭
$0.693
$46.53
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
명칭
Bioaffinity Technologies Inc
전화
210-698-5334
주소
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
2.97 | 10.93M | 6.78M | -14.74M | -8.51M | -16.13 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
What's Going On With bioAffinity Stock Thursday? - Benzinga
BioAffinity Technologies posts 2025 results as CyPath lung testing growth accelerates - MSN
bioAffinity Showcases CyPath Lung Case Study in Diagnostics - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows noninvasive option - Stock Titan
Top Biotech Stocks To Follow TodayMarch 17th - MarketBeat
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures - BioSpace
Crude Oil Gains Around 2%; Elbit Systems Shares Jump On Upbeat Earnings - Benzinga
BioAffinity Technologies Eyes Further Expansion Amid Growing Market Demand - StocksToTrade
Why Is bioAffinity Technologies Stock Surging Tuesday? - Benzinga
CyPath Lung Diagnostic Tool Spurs bioAffinity Technologies’ Growth - timothysykes.com
Can bioAffinity Technologies Inc Equity Warrant weather a recessionDip Buying & Reliable Price Breakout Signals - baoquankhu1.vn
BioAffinity Technologies, Inc. Releases New Clinical Case Study That Highlights the Benefit of Adding CyPath Lung - marketscreener.com
BioAffinity Technologies stock cools off after strong Friday rallyhere's why - MSN
bioAffinity (NASDAQ: BIAF) proxy adds reverse split and major share authorizations - Stock Titan
bioAffinity Technologies 2024 Annual Report: Business Overview, Clinical Trial Updates, and Key Risks for Diagnostic and Therapeutic Product Development - Minichart
bioAffinity Technologies Stock Cools Off After Strong Friday RallyHere's Why - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
bioAffinity Technologies 10-K: Revenue $6.16M, EPS $(8.66) - TradingView
Best Small Cap Stocks To Add to Your WatchlistMarch 15th - MarketBeat
Promising Biotech Stocks To Add to Your WatchlistMarch 15th - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Biotech Stocks To Watch NowMarch 14th - MarketBeat
BioAffinity Technologies Projects Strong Growth Amid Market Fluctuations - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
bioAffinity Technologies reports 2025 financial results - Investing.com India
bioAffinity Technologies reports 2025 financial results By Investing.com - Investing.com Australia
Small Cap Stocks To Follow TodayMarch 13th - MarketBeat
Medical Stocks Worth WatchingMarch 13th - MarketBeat
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Benzinga
bioAffinity Technologies Expands Lung Cancer Detection Initiatives - StocksToTrade
bioAffinity Technologies jumps 124% as it touts record 2025 CyPath Lung growth and outlines expansion plans - Quiver Quantitative
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
BioAffinity Technologies Shakes Up Diagnostics Field with Innovative Clinical Initiatives - timothysykes.com
Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 - Benzinga
BIAF: CyPath® Lung test sales surged 99% in 2025, driving record revenue and future growth momentum - TradingView
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - itemonline.com
[10-K] bioAffinity Technologies, Inc. Files Annual Report | BIAF SEC FilingForm 10-K - Stock Titan
BIAF vs. GH: Which cancer detection stock is the better buy now? - MSN
bioAffinity launches 2,000-patient study for noninvasive lung cancer test - Mugglehead Magazine
Volume Recap: Can bioAffinity Technologies Inc lead its sector in growth2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
BioAffinity launches large-scale clinical study for lung cancer detection technology - MSN
Study Begins for bioAffinity Technologies’ CyPath Lung Cancer Diagnostic - Medical Product Outsourcing
CyPath Lung Expands Diagnostic Capabilities as bioAffinity Grows Board - StocksToTrade
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Non - pharmiweb.com
bioAffinity Launches Major Lung Cancer Detection Study - TipRanks
2,000-patient CyPath Lung trial launched by bioAffinity (NASDAQ: BIAF) - Stock Titan
BioAffinity Technologies initiates clinical study for CyPath Lung - TipRanks
Bioaffinity Technologies Inc (BIAF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):